Cell Medica given $8.7 million to develop cancer therapy
Cell Medica has been awarded a $8.7 million CPRIT grant to accelerate its CMD-502 cell therapy into clinical development.
Read More
Tag: Cell Medica
Cell Medica links with UCL in research deal
Cell Medica has signed a research deal with University College London for access to its novel T cell receptor technology, in a bid to generate leading-edge modified TCR products for the treatment of cancer.
Read More
EU orphan status for Cell Medica drug
London, UK-based Cell Medica has received European Commission orphan drug designations for its lead cancer immunotherapy CMD-003 (baltaleucel-T).
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
